HFS
PCVX icon

Hantz Financial Services’s Vaxcyte PCVX Stock Holding History

Hantz Financial Services’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Sell
19
-7
-27% -$380 ﹤0.01% 2402
2026
Q1 		$2K Buy
26
+7
+37% +$380 ﹤0.01% 2300
2025
Q4 		$1K Buy
+19
New +$850 ﹤0.01% 2351

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Hantz Financial Services's PCVX Position: Q2 2026 in Review

Hantz Financial Services reduced its Vaxcyte (PCVX) stake by 27% in Q2 2026, selling an estimated $380 and leaving 19 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2402.

Hantz Financial Services first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2K in Q1 2026. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Hantz Financial Services held 19 shares of Vaxcyte worth $1K as of Q2 2026.
  • Hantz Financial Services sold 7 Vaxcyte shares in Q2 2026, an estimated $380.
  • Vaxcyte made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2402 holding.
  • Hantz Financial Services first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • Hantz Financial Services's Vaxcyte position peaked at $2K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.